Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 7, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

506

Lapatinib.

Minna Voigtlaender1, Tanja Schneider-Merck1,2, Martin Trepel3,4

  • 1Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Cancer prevention and screening].

Innere Medizin (Heidelberg, Germany)·2026
Same author

Mass Dose Effects in FAP-Directed Imaging: Influence of Administered Dose of [<sup>68</sup>Ga]Ga-LNTH-1363S on Image Quality.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.

Acta neuropathologica·2026
Same author

Clinical Significance and Therapeutic Potential of Long Non-Coding RNA H19 in Soft Tissue Sarcoma.

Cancer medicine·2026
Same author

Large language model processing capabilities of ChatGPT 4.0 to generate molecular tumor board recommendations-a critical evaluation on real world data.

The oncologist·2025
Same author

Correction: Identification of AAV variants with improved transduction of human vascular endothelial cells by screening AAV capsid libraries in non-human primates.

Gene therapy·2025

Lapatinib, an oral HER2-targeted therapy, shows efficacy in advanced HER2-positive breast cancer but has seen reduced importance due to newer agents. It remains a viable option for selected patients, especially those with cardiac risks.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The human epidermal growth factor receptor (HER) family, particularly HER2, is crucial in various cancers, including breast and gastrointestinal cancers.
  • HER2 overexpression in breast cancer is linked to aggressive disease, historically managed with trastuzumab.
  • Lapatinib, a dual tyrosine kinase inhibitor, targets HER1 and HER2 intracellularly to inhibit tumor growth.

Purpose of the Study:

  • To review the role and evolving significance of lapatinib in HER2-positive cancer treatment.
  • To assess lapatinib's efficacy, approved indications, and limitations compared to other HER2-targeted therapies.
  • To explore potential future applications and advantages of lapatinib.

Main Methods:

  • Review of clinical trial data and regulatory approvals for lapatinib in HER2-positive cancers.
Keywords:
Breast cancerGastric cancerHER2LapatinibTyrosine kinase inhibitor

Related Experiment Videos

Last Updated: Feb 7, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

506
  • Comparative analysis of lapatinib versus trastuzumab and other novel HER2-targeted agents.
  • Evaluation of lapatinib's safety profile, including adverse effects and cardiac toxicity.

    • Main Results:

    • Lapatinib is approved for advanced HER2-positive breast cancer in specific settings, often in combination therapies.
    • Clinical trials have not consistently shown lapatinib's superiority over trastuzumab in first-line settings.
    • Novel HER2-targeted drugs have demonstrated more favorable outcomes, diminishing lapatinib's prominence.
    • Lapatinib may offer advantages in targeting truncated HER2 and crossing the blood-brain barrier, with a favorable cardiac safety profile.

    Conclusions:

    • While lapatinib's importance has waned with the advent of newer therapies, it remains a valuable option for selected patients with HER2-positive cancers.
    • Its distinct properties, including potential efficacy against truncated HER2 and a favorable cardiac profile, warrant continued consideration.
    • Further indications, such as in refractory metastatic colorectal cancer, may emerge for lapatinib.